IL131872A0 - Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors - Google Patents

Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors

Info

Publication number
IL131872A0
IL131872A0 IL13187298A IL13187298A IL131872A0 IL 131872 A0 IL131872 A0 IL 131872A0 IL 13187298 A IL13187298 A IL 13187298A IL 13187298 A IL13187298 A IL 13187298A IL 131872 A0 IL131872 A0 IL 131872A0
Authority
IL
Israel
Prior art keywords
benzothiepines
hmg
composition
bile acid
reductase inhibitors
Prior art date
Application number
IL13187298A
Other languages
English (en)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21912237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL131872(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Searle & Co filed Critical Searle & Co
Publication of IL131872A0 publication Critical patent/IL131872A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL13187298A 1997-03-11 1998-03-10 Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors IL131872A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4066097P 1997-03-11 1997-03-11
PCT/US1998/003792 WO1998040375A2 (en) 1997-03-11 1998-03-10 COMBINATION OF ILEAL BILE ACID TRANSPORT INHIBITING BENZOTHIEPINES AND HMG Co-A REDUCTASE INHIBITORS

Publications (1)

Publication Number Publication Date
IL131872A0 true IL131872A0 (en) 2001-03-19

Family

ID=21912237

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13187298A IL131872A0 (en) 1997-03-11 1998-03-10 Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors

Country Status (16)

Country Link
EP (1) EP0971744A2 (https=)
JP (1) JP2002500628A (https=)
CN (1) CN1255864A (https=)
AU (1) AU730024C (https=)
BG (1) BG103793A (https=)
BR (1) BR9808013A (https=)
CA (1) CA2283575A1 (https=)
HU (1) HUP0002395A3 (https=)
IL (1) IL131872A0 (https=)
MX (1) MXPA99008417A (https=)
NO (1) NO994390L (https=)
NZ (1) NZ337830A (https=)
PL (1) PL336415A1 (https=)
RU (1) RU2247579C2 (https=)
SK (1) SK125099A3 (https=)
WO (1) WO1998040375A2 (https=)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6083497A (en) 1997-11-05 2000-07-04 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with unsubstituted polydiallylamine polymers
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
WO2000038721A1 (en) 1998-12-23 2000-07-06 G.D. Searle Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
AU2003241629B2 (en) * 1999-04-19 2005-06-16 Astrazeneca Ab An oral formulation for ileum administering comprising an inhibitor compound of the ileal bile acid transport
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
SE0003766D0 (sv) * 2000-10-18 2000-10-18 Astrazeneca Ab Novel formulation
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
WO2002051396A1 (en) * 2000-12-26 2002-07-04 Sankyo Company, Limited Pharmaceutical compositions containing cyclobutene derivatives
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
AU2002329387B2 (en) 2001-09-08 2007-06-07 Albireo Ab Benzothiazepine and benzothiadiazepine derivatives with ileal bile acid transport (IBAT) inhibitory activity for the treatment hyperlipidaemia
IL162533A0 (en) 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
US6852753B2 (en) 2002-01-17 2005-02-08 Pharmacia Corporation Alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (ASBT) and taurocholate uptake
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
CN100494185C (zh) * 2002-08-28 2009-06-03 旭化成制药株式会社 新型季铵化合物
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
KR20070026392A (ko) 2004-02-27 2007-03-08 아사히 가세이 파마 가부시키가이샤 신규 벤조티아제핀 및 벤조티에핀 화합물
ES2552657T3 (es) 2010-05-26 2015-12-01 Satiogen Pharmaceuticals, Inc. Inhibidores del reciclado de ácidos biliares y saciógenos para el tratamiento de diabetes, obesidad, y afecciones gastrointestinales inflamatorias
ES2687027T3 (es) 2010-11-04 2018-10-23 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepáticas
DK2637646T3 (en) 2010-11-08 2016-08-29 Albireo Ab PHARMACEUTICAL COMBINATION CONTAINING AN IBAT inhibitor and a bile acid binder
AU2012328526B2 (en) 2011-10-28 2017-05-25 Shire Human Genetic Therapies, Inc. Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
US20130108573A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
CA2907230A1 (en) 2013-03-15 2014-09-18 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
AU2014229050A1 (en) 2013-03-15 2015-10-22 Lumena Pharmaceuticals Llc Bile acid recycling inhibitors for treatment of Barrett's esophagus and gastroesophageal reflux disease
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
CN106659726A (zh) 2014-06-25 2017-05-10 Ea制药株式会社 固体制剂及其着色防止或着色减少方法
EP3197459B1 (en) * 2014-09-28 2025-02-12 Huahui Health Ltd. Polymeric bile acid derivatives inhibit hepatitis b and d virus and ntcp transport
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
WO2017138878A1 (en) 2016-02-09 2017-08-17 Albireo Ab Oral cholestyramine formulation and use thereof
ES2874669T3 (es) 2016-02-09 2021-11-05 Albireo Ab Formulación oral de colestiramina y uso de la misma
CN108601739B (zh) 2016-02-09 2022-01-04 阿尔比里奥公司 考来烯胺丸剂及其制备方法
EP3664782B1 (en) 2017-08-09 2025-01-29 Albireo AB Cholestyramine pellets, oral cholestyramine formulations and medical use thereof
CN111032019B (zh) 2017-08-09 2022-07-05 阿尔比里奥公司 考来烯胺颗粒、口服考来烯胺制剂及其用途
SG11202001685TA (en) 2017-08-28 2020-03-30 Enanta Pharm Inc Hepatitis b antiviral agents
CN112449637B (zh) 2018-06-05 2024-03-19 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
PL3810581T3 (pl) 2018-06-20 2025-04-28 Albireo Ab Modyfikacje kryształu odewiksibatu
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
IL283190B2 (en) 2018-11-21 2025-08-01 Enanta Pharm Inc Functionalized heterocycles as antiviral agents
TWI835997B (zh) 2019-02-06 2024-03-21 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其用作膽酸調節劑之用途
CN118852054A (zh) 2019-02-06 2024-10-29 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
EP3923943B1 (en) 2019-02-12 2024-07-31 Mirum Pharmaceuticals, Inc. Genotype and dose-dependent response to an asbti in patients with bile salt export pump deficiency
WO2021110883A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7696898B2 (ja) 2019-12-04 2025-06-23 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
EP4069247B1 (en) 2019-12-04 2025-03-26 Albireo AB Benzothiadiazepine compounds and their use as bile acid modulators
IL293379B2 (en) 2019-12-04 2026-04-01 Albireo Ab Benzothia(dia)azepine compounds and their use as bile acid modulators
AR120676A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como ácido biliar
WO2021110884A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
WO2021110887A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
TWI877263B (zh) 2019-12-04 2025-03-21 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
ES2973355T3 (es) 2019-12-04 2024-06-19 Albireo Ab Compuestos de benzotia(di)azepina y su uso como moduladores del ácido biliar
EP4188541B1 (en) 2020-08-03 2024-12-25 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
CA3196488A1 (en) 2020-11-12 2022-05-19 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
CN112274648B (zh) * 2020-11-23 2022-10-14 郑州大学 一种胆固醇氧化酶修饰的杂化金属有机框架肿瘤靶向纳米制剂的制备方法
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
TW202313579A (zh) 2021-06-03 2023-04-01 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯(benzothia(di)azepine)化合物及其作為膽酸調節劑之用途
KR20250022025A (ko) 2022-06-09 2025-02-14 알비레오 에이비 간염 치료
TW202423921A (zh) * 2022-08-22 2024-06-16 美商安塔製藥公司 稠合的雜雙環抗病毒劑
WO2025146508A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2025146507A1 (en) 2024-01-05 2025-07-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
EP0549967B1 (de) * 1991-12-20 1996-03-13 Hoechst Aktiengesellschaft Polymere und Oligomere von Gallensäurederivaten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
GB9203347D0 (en) * 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds

Also Published As

Publication number Publication date
JP2002500628A (ja) 2002-01-08
BG103793A (en) 2000-07-31
WO1998040375A2 (en) 1998-09-17
EP0971744A2 (en) 2000-01-19
RU2247579C2 (ru) 2005-03-10
NZ337830A (en) 2001-07-27
MXPA99008417A (es) 2005-02-03
HUP0002395A2 (hu) 2001-05-28
WO1998040375A3 (en) 1998-12-03
CA2283575A1 (en) 1998-09-17
HUP0002395A3 (en) 2002-12-28
NO994390D0 (no) 1999-09-10
AU6440898A (en) 1998-09-29
PL336415A1 (en) 2000-06-19
NO994390L (no) 1999-11-04
AU730024C (en) 2004-08-05
BR9808013A (pt) 2001-09-25
CN1255864A (zh) 2000-06-07
AU730024B2 (en) 2001-02-22
SK125099A3 (en) 2001-02-12

Similar Documents

Publication Publication Date Title
IL131872A0 (en) Composition comprising an ileal bile acid transport inhibiting benzothiepines and hmg co-a reductase inhibitors
PL346324A1 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
HUP0301087A3 (en) Oral pharmaceutical composition comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
HUP9903047A3 (en) Novel benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
PL348609A1 (en) Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
IL143947A0 (en) Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
HUP0104593A3 (en) Combinations of benzothiepine ileal bile acid transport inhibitor and nicotinic acid derivatives for cardiovascular indications
HUP0105409A3 (en) 1,2-benzothiazepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake, use thereof and pharmaceutical compositions containing them
EP0971723A4 (en) COMPOSITIONS AND METHODS FOR INHIBITING CELL PROLIFERATION
SG77665A1 (en) A system for electronic placement and broadcast of an advertisement
HUP0004533A3 (en) Microorganism reduction methods and compositions for food
IL130150A0 (en) Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
EP0737075A4 (en) COMPOSITIONS AND METHODS FOR TRANSPORTERS OF ILEAL BILIC ACID
AU6296198A (en) Dicarboxylic acid crystallizates
GB2319530B (en) Low toxic corrosion inhibitor
ZA988934B (en) Method and composition for inhibiting corrosion
AU4577999A (en) Methods and compositions for inhibiting corrosion
HUP0002103A3 (en) Hmg-coa reductase inhibitor preparation process
GB9612442D0 (en) Biodegradation of metal cyanides
HUP0201597A3 (en) Antilipemic combunations comprising hmg-coa reductase inhibitors and carnitines
AU8968598A (en) Bovine footrot treatment and prevention
SI1091953T1 (en) Novel benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
HK1057485A (en) Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor
AU2399497A (en) Simple effective electronic ballast
AU3148500A (en) Scale and corrosion inhibitor